The DEA: Four Decades of Impeding And Rejecting Science
This report, co-published by DPA and MAPS, illustrates a decades-long pattern of behavior that demonstrates the Drug Enforcement Administration’s (DEA’s) inability to exercise its responsibilities in a fair and impartial manner or to act in accord with the scientific evidence. The report’s case studies reveal a number of DEA practices that maintain the existing, scientifically unsupported drug scheduling system and obstruct research that might alter current drug schedules. In addition to marijuana, the report also examines the DEA's speed in moving to ban MDMA, synthetic cannabinoids, and synthetic stimulants. In contrast to the DEA's failure to act in a timely fashion when confronted with evidence for scheduling certain drugs less severely, the agency has shown repeatedly that it can move quickly when it wants to prohibit a substance. The report recommends that responsibility for determining drug classifications and other health determinations should be completely removed from the DEA and transferred to another agency, perhaps even a non-governmental entity such as the National Academy of Sciences. The report also recommends the DEA should be ordered to end the federal government’s unjustifiable monopoly on the supply of research-grade marijuana available for federally approved research. No other drug is available from only a single governmental source for research purposes.